[go: up one dir, main page]

WO2004087880A8 - Compounds and their use to treat diabetes and related disorders - Google Patents

Compounds and their use to treat diabetes and related disorders

Info

Publication number
WO2004087880A8
WO2004087880A8 PCT/US2004/009342 US2004009342W WO2004087880A8 WO 2004087880 A8 WO2004087880 A8 WO 2004087880A8 US 2004009342 W US2004009342 W US 2004009342W WO 2004087880 A8 WO2004087880 A8 WO 2004087880A8
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
related disorders
treat diabetes
diabetes
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/009342
Other languages
French (fr)
Other versions
WO2004087880A2 (en
WO2004087880A3 (en
Inventor
William H Bullock
Qingjie Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Priority to JP2006509358A priority Critical patent/JP2006521400A/en
Priority to US10/543,070 priority patent/US20060094714A1/en
Priority to EP04758414A priority patent/EP1613318A4/en
Publication of WO2004087880A2 publication Critical patent/WO2004087880A2/en
Publication of WO2004087880A8 publication Critical patent/WO2004087880A8/en
Publication of WO2004087880A3 publication Critical patent/WO2004087880A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention relates generally to compounds described herein. More specifically, the invention relates to compounds and pharmaceutical compositions containing such compounds. Methods of the invention comprise administration of a compound of the invention for the treatment of diabetes and related disorders.
PCT/US2004/009342 2003-03-26 2004-03-26 Compounds and their use to treat diabetes and related disorders Ceased WO2004087880A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2006509358A JP2006521400A (en) 2003-03-26 2004-03-26 Compounds for the treatment of diabetes and related disorders and their use
US10/543,070 US20060094714A1 (en) 2004-03-26 2004-03-26 Compounds and their use to treat diabetes and related disorders
EP04758414A EP1613318A4 (en) 2003-03-26 2004-03-26 Compounds and their use to treat diabetes and related disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45819403P 2003-03-26 2003-03-26
US60/458,194 2003-03-26

Publications (3)

Publication Number Publication Date
WO2004087880A2 WO2004087880A2 (en) 2004-10-14
WO2004087880A8 true WO2004087880A8 (en) 2005-01-13
WO2004087880A3 WO2004087880A3 (en) 2005-03-10

Family

ID=33131765

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/009342 Ceased WO2004087880A2 (en) 2003-03-26 2004-03-26 Compounds and their use to treat diabetes and related disorders

Country Status (3)

Country Link
EP (1) EP1613318A4 (en)
JP (1) JP2006521400A (en)
WO (1) WO2004087880A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470700B2 (en) 2003-08-13 2008-12-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7550590B2 (en) 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1625122A1 (en) 2003-05-14 2006-02-15 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US20070060530A1 (en) 2005-09-14 2007-03-15 Christopher Ronald J Administration of dipeptidyl peptidase inhibitors
EP1924567B1 (en) 2005-09-16 2012-08-22 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
KR102767739B1 (en) 2018-06-27 2025-02-12 브리스톨-마이어스 스큅 컴퍼니 Substituted naphthyridinone compounds useful as T cell activators
SMT202300170T1 (en) 2018-06-27 2023-09-06 Bristol Myers Squibb Co Naphthyridinone compounds useful as t cell activators
AR119821A1 (en) 2019-08-28 2022-01-12 Bristol Myers Squibb Co SUBSTITUTED PYRIDOPYRIMIDINOL COMPOUNDS USEFUL AS T-CELL ACTIVATORS
AR120823A1 (en) 2019-12-23 2022-03-23 Bristol Myers Squibb Co SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T-CELL ACTIVATORS
US12454531B2 (en) 2019-12-23 2025-10-28 Bristol-Myers Squibb Company Substituted piperazine derivatives useful as T cell activators
KR20220119454A (en) 2019-12-23 2022-08-29 브리스톨-마이어스 스큅 컴퍼니 Substituted Quinazolinyl Compounds Useful as T Cell Activators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4350817A (en) * 1980-02-28 1982-09-21 American Home Products Corporation 4-Cl, Br or I-3-Carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
JPH07126268A (en) * 1993-10-29 1995-05-16 Otsuka Pharmaceut Factory Inc 1,8-naphthyridine derivative
KR970705562A (en) * 1994-08-29 1997-10-09 오노다 마사요시 Novel naphthyridine derivatives and medicinal composition thereof.
WO2005047285A1 (en) * 2003-11-04 2005-05-26 Merck & Co., Inc. Substituted naphthyridinone derivatives

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550590B2 (en) 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7470700B2 (en) 2003-08-13 2008-12-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7579357B2 (en) 2003-08-13 2009-08-25 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors

Also Published As

Publication number Publication date
EP1613318A4 (en) 2009-03-11
EP1613318A2 (en) 2006-01-11
WO2004087880A2 (en) 2004-10-14
JP2006521400A (en) 2006-09-21
WO2004087880A3 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
WO2005046603A3 (en) Pyridine compounds
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2006086562A3 (en) Phenylazetidinone derivatives
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2001081310A8 (en) 1-aroyl-piperidinyl benzamidines
WO2005002515A3 (en) Delivery of therapeutic compounds to the brain and other tissues
WO2007064883A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
EP2305640A3 (en) Substituted diphenyl-ethers, -amines, -sulfides and -methanes for the treatment of respiratory diseases
WO2004037789A8 (en) Methylene urea derivatives as raf-kinase inhibitors
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2006099943A8 (en) Amide-substituted 8-n-benzimidazoles, method for the production thereof, and use of the same as medicaments
WO2004087880A8 (en) Compounds and their use to treat diabetes and related disorders
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
WO2005080352A3 (en) Quinazoline derivatives and therapeutic use thereof
WO2002030405A3 (en) Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
WO2003087062A3 (en) 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
WO2004098594A3 (en) Dosage form containing pantoprazole as active ingredient
WO2003037863A3 (en) Substituted indoles, method for production and use thereof for the inhibition of pain
WO2005004854A3 (en) Use of betaine for treating arteritis
WO2007104933A8 (en) Chemical compounds
WO2004098577A3 (en) Dosage form containing (s)-pantoprazole as active ingredient
WO2004098522A3 (en) Gemini vitamin d3 compounds and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 42/2004 UNDER "PUBLISHED" ADD "WITH DECLARATION"

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase in:

Ref document number: 2006094714

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10543070

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2006509358

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004758414

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004758414

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10543070

Country of ref document: US